A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. 1999

W E Pelham, and H R Aronoff, and J K Midlam, and C J Shapiro, and E M Gnagy, and A M Chronis, and A N Onyango, and G Forehand, and A Nguyen, and J Waxmonsky
Department of Psychology, State University of New York at Buffalo, Buffalo, New York 14260, USA.

OBJECTIVE Very little research has focused on the efficacy of Adderall (Shire-Richwood Inc, Florence, KY) in the treatment of children with attention-deficit/hyperactivity disorder (ADHD), and no studies have compared it with standardized doses of Ritalin (Novartis Pharmaceuticals, East Hanover, NJ). It is thought that Adderall has a longer half-life than Ritalin and might minimize the loss of efficacy that occurs 4 or 5 hours after Ritalin ingestion. We compared two doses of Ritalin and Adderall in the treatment of ADHD in children in an acute study and assessed the medications' time courses. METHODS Within-subject, double-blind, placebo-controlled, crossover design lasting 6 weeks. As in our previous work, medication changes occurred on a daily basis in random order over days. METHODS Eight-week, weekday (9 hours daily) summer treatment program at the State University of New York at Buffalo, using an intensive behavioral treatment program including a point system and parent training. METHODS Twenty-five children (21 boys and 4 girls) diagnosed as ADHD using standardized structured interview and rating scales, mean age 9.6 years, 88% Caucasian, of average intelligence, with no medical conditions that would preclude a trial of stimulant medication. Thirteen were comorbid for oppositional-defiant disorder and another 8 for conduct disorder. METHODS Children received 10 mg of Ritalin, 17.5 mg of Ritalin, 7.5 mg of Adderall, 12.5 mg of Adderall, or placebo, twice a day (7:45 AM and 12:15 PM), in random order with conditions changing daily for 24 days. METHODS Daily rates of behaviors in recreational and classroom settings, and standardized ratings from counselors, teachers, and parents, were averaged across days within condition within child and compared. Within-subject relative sizes of the medication effects were computed by taking the placebo-minus-drug mean difference divided by the placebo standard deviation for each child, and were compared hourly between first daily ingestion (7:45 AM) and 5:00 PM to assess the time course of the two drugs. Measures were taken at 12:00 PM (recess rule violations) and at 5:00 PM (parent behavior ratings) to determine whether Adderall was still effective at times when the effects of Ritalin should have worn off. Parent ratings were also made for evening behavior to assess possible rebound, and side effects ratings were obtained from parents, counselors, and teachers. Parents, counselors, and teachers also rated their perceptions of medication status and whether they recommended the continued use of the medication given that day. Finally, a clinical team made recommendations for treatment taking into account each child's individual response. RESULTS Both drugs were routinely superior to placebo and produced dramatic improvements in rates of negative behavior, academic productivity, and staff/parent ratings of behavior. The doses of Adderall that were assessed produced greater improvement than did the assessed doses of Ritalin, particularly the lower dose of Ritalin, on numerous but not all measures. This result suggests that the doses of Adderall used were functionally more potent than those for Ritalin. Adderall was generally superior to the low dose of Ritalin when the effects of Ritalin were wearing off at midday and late afternoon/early evening. The lower dose of Adderall produced effects comparable to those of the higher dose of Ritalin. Both drugs produced low and comparable levels of clinically significant side effects. Staff clinical recommendations for continued medication favored Adderall three to one. Almost 25% of the study participants were judged to be nonresponders by the clinical team, presumably because of their large beneficial response to the concurrent behavioral intervention and minimal incremental benefit from medication. CONCLUSIONS This is the first investigation to assess comparable doses of Adderall and Ritalin directly. (ABSTRACT TRU

UI MeSH Term Description Entries
D008297 Male Males
D008774 Methylphenidate A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE. Centedrin,Concerta,Daytrana,Equasym,Metadate,Methylin,Methylphenidate Hydrochloride,Phenidylate,Ritalin,Ritalin-SR,Ritaline,Tsentedrin,Hydrochloride, Methylphenidate,Ritalin SR
D010290 Parents Persons functioning as natural, adoptive, or substitute parents. The heading includes the concept of parenthood as well as preparation for becoming a parent. Step-Parents,Parental Age,Parenthood Status,Stepparent,Age, Parental,Ages, Parental,Parent,Parental Ages,Status, Parenthood,Step Parents,Step-Parent,Stepparents
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000662 Amphetamines Analogs or derivatives of AMPHETAMINE. Many are sympathomimetics and central nervous system stimulators causing excitation, vasopressin, bronchodilation, and to varying degrees, anorexia, analepsis, nasal decongestion, and some smooth muscle relaxation.

Related Publications

W E Pelham, and H R Aronoff, and J K Midlam, and C J Shapiro, and E M Gnagy, and A M Chronis, and A N Onyango, and G Forehand, and A Nguyen, and J Waxmonsky
September 2002, Journal of attention disorders,
W E Pelham, and H R Aronoff, and J K Midlam, and C J Shapiro, and E M Gnagy, and A M Chronis, and A N Onyango, and G Forehand, and A Nguyen, and J Waxmonsky
October 2002, Journal of clinical psychopharmacology,
W E Pelham, and H R Aronoff, and J K Midlam, and C J Shapiro, and E M Gnagy, and A M Chronis, and A N Onyango, and G Forehand, and A Nguyen, and J Waxmonsky
May 1997, Harefuah,
W E Pelham, and H R Aronoff, and J K Midlam, and C J Shapiro, and E M Gnagy, and A M Chronis, and A N Onyango, and G Forehand, and A Nguyen, and J Waxmonsky
November 1994, The Medical letter on drugs and therapeutics,
W E Pelham, and H R Aronoff, and J K Midlam, and C J Shapiro, and E M Gnagy, and A M Chronis, and A N Onyango, and G Forehand, and A Nguyen, and J Waxmonsky
January 2001, Journal of child and adolescent psychopharmacology,
W E Pelham, and H R Aronoff, and J K Midlam, and C J Shapiro, and E M Gnagy, and A M Chronis, and A N Onyango, and G Forehand, and A Nguyen, and J Waxmonsky
December 2006, European child & adolescent psychiatry,
W E Pelham, and H R Aronoff, and J K Midlam, and C J Shapiro, and E M Gnagy, and A M Chronis, and A N Onyango, and G Forehand, and A Nguyen, and J Waxmonsky
January 2014, Iranian journal of psychiatry and behavioral sciences,
W E Pelham, and H R Aronoff, and J K Midlam, and C J Shapiro, and E M Gnagy, and A M Chronis, and A N Onyango, and G Forehand, and A Nguyen, and J Waxmonsky
August 2005, Harefuah,
W E Pelham, and H R Aronoff, and J K Midlam, and C J Shapiro, and E M Gnagy, and A M Chronis, and A N Onyango, and G Forehand, and A Nguyen, and J Waxmonsky
January 2017, Advanced biomedical research,
W E Pelham, and H R Aronoff, and J K Midlam, and C J Shapiro, and E M Gnagy, and A M Chronis, and A N Onyango, and G Forehand, and A Nguyen, and J Waxmonsky
January 2005, Development and psychopathology,
Copied contents to your clipboard!